{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:54:42Z","timestamp":1791093282174,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.ahj.2010.10.043","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T14:49:29Z","timestamp":1299682169000},"page":"450-461","source":"Crossref","is-referenced-by-count":29,"title":["Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions"],"prefix":"10.1016","volume":"161","author":[{"given":"Harvey D.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2010.10.043_bb0005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH09-03-0192","article-title":"Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis","volume":"102","author":"Jennings","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0015","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical aspects of platelet inhibitors and thrombus formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2010.10.043_bb0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein\u2013coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2010.10.043_bb0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","article-title":"Cell adhesion mechanisms in platelets","volume":"28","author":"Varga-Szabo","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2010.10.043_bb0035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0040","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.ahj.2010.10.043_bb0055","doi-asserted-by":"crossref","first-page":"9C","DOI":"10.1016\/j.amjcard.2009.06.020","article-title":"Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction","volume":"104","author":"Manoukian","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0060","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.10.043_bb0065","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0070","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non\u2013ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"Mehran","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1 Suppl","key":"10.1016\/j.ahj.2010.10.043_bb0080","doi-asserted-by":"crossref","first-page":"321S","DOI":"10.1378\/chest.119.1_suppl.321S","article-title":"Antithrombotic therapy in patients undergoing percutaneous coronary intervention","volume":"119","author":"Popma","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2010.10.043_bb0085","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0090","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0095","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0100","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0105","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0120","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2010.10.043_bb0125","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0135","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ahj.2010.10.043_bb0140","series-title":"Effient (prasugrel) tablets [prescribing information]","year":"2009"},{"key":"10.1016\/j.ahj.2010.10.043_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1538-7836.2009.03648.x","article-title":"The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19\u204e2 genotype: first experience in patients","volume":"8","author":"Gurbel","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0150","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"issue":"suppl)(16","key":"10.1016\/j.ahj.2010.10.043_bb0155","first-page":"II","article-title":"Thrombin receptor antagonist (TRA;SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics","volume":"116","author":"Jennings","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.10.043_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"Leonardi","year":"2010","journal-title":"Am Heart J"},{"issue":"suppl 1","key":"10.1016\/j.ahj.2010.10.043_bb0165","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.3949\/ccjm.76.s1.02","article-title":"Novel antiplatelet strategies in acute coronary syndromes","volume":"76","author":"Sabatine","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.18553\/jmcp.2009.15.4.335","article-title":"Critical review of prasugrel for formulary decision makers","volume":"15","author":"Schafer","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ahj.2010.10.043_bb0175","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.bjp.0703237","article-title":"The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties","volume":"129","author":"Sugidachi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0180","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2010.10.043_bb0185","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncpcardio1372","article-title":"Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future","volume":"5","author":"Raju","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ahj.2010.10.043_bb0190","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2010.10.043_bb0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0200","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2010.10.043_bb0205","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","volume":"160","author":"Chin","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0215","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0220","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ahj.2009.10.010","volume":"158","author":"Berger","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0225","author":"Rao","year":"2010"},{"key":"10.1016\/j.ahj.2010.10.043_bb0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1073\/pnas.0610188104","article-title":"Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis","volume":"104","author":"Vandendries","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ahj.2010.10.043_bb0235","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1124\/jpet.102.042663","article-title":"Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates","volume":"304","author":"Derian","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ahj.2010.10.043_bb0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01973-3","article-title":"Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig","volume":"473","author":"Kato","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0245","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0037-1617133","article-title":"Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1","volume":"29","author":"Hildemann","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ahj.2010.10.043_bb0255","first-page":"e138","article-title":"SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys","volume":"28","author":"Chintala","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2010.10.043_bb0260","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"J Atheroscler Thromb"},{"issue":"suppl 1)(3","key":"10.1016\/j.ahj.2010.10.043_bb0265","first-page":"139","article-title":"A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke","author":"Shinohara","year":"2008","journal-title":"Int J Stroke"},{"key":"10.1016\/j.ahj.2010.10.043_bb0270","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"Morrow","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ahj.2009.07.001","article-title":"The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA\u204eCER) trial: study design and rationale","volume":"158","author":"TRA\u204eCER Executive and Steering Committees","year":"2009","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.ahj.2010.10.043_bb0280","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1021\/jm0603670","article-title":"Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects","volume":"49","author":"Chackalamannil","year":"2006","journal-title":"J Med Chem"},{"issue":"Suppl 2","key":"10.1016\/j.ahj.2010.10.043_bb0285","article-title":"Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro","volume":"5","author":"Kogushi","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0290","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","article-title":"The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease","volume":"102","author":"Serebruany","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0295","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","article-title":"Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease","volume":"31","author":"Goto","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2010.10.043_bb0300","article-title":"LANCELOT ACS: a prospective, randomized, double-blind, placebo-controlled trial of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndromes","author":"O'Donoghue","year":"2010"},{"issue":"Suppl 2","key":"10.1016\/j.ahj.2010.10.043_bb0305","article-title":"PR-15 A novel intravenous inhibitor of platelet adhesion: a phase I dose ascending pharmacokinetic, pharmacodynamic, and tolerance study","volume":"5","author":"Combe","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2010.10.043_bb0310","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH09-06-0378","article-title":"A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study","volume":"103","author":"Zafar","year":"2010","journal-title":"Thromb Haemost"},{"issue":"Suppl 3","key":"10.1016\/j.ahj.2010.10.043_bb0315","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000209262","article-title":"TP receptor antagonism: a new concept in atherothrombosis and stroke prevention","volume":"27","author":"Chamorro","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ahj.2010.10.043_bb0320","first-page":"93","article-title":"A review of picotamide in the reduction of cardiovascular events in diabetic patients","volume":"3","author":"Celestini","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ahj.2010.10.043_bb0325","unstructured":"Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it. Pub. No: WO\/2009\/093972. July 30, 2009.; World Intellectual Property Organization. (Available online at: http:\/\/www.wipo.int\/pctdb\/en\/wo.jsp?WO=2009093972&IA=SE2009050065&DISPLAY=STATUS). Last accessed September 29, 2010."}],"updated-by":[{"DOI":"10.1016\/j.ahj.2011.07.025","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000}}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310011749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870310011749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T04:50:01Z","timestamp":1637383801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870310011749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0002870310011749"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2010.10.043","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}